BioCentury
ARTICLE | Clinical News

Delenex's DLX105 misses in psoriasis Phase II

September 13, 2014 1:33 AM UTC

Delenex Therapeutics AG (Zurich, Switzerland) said DLX105 led to no significant clinical improvements in a Phase II trial in mild to moderate plaque psoriasis. The co-primary efficacy endpoints were local Psoriasis Area Severity Index (PASI) score per plaque vs. baseline and placebo. ...